Robocath

What Robocath does

Robocath is a French medical robotics company founded in 2009 by Philippe Bencteux, MD, and headquartered in Rouen, France, that designs, develops, and commercializes robotic platforms for the treatment of vascular diseases. Its flagship product, the R-One+ robotic system, assists interventional cardiologists in performing percutaneous coronary intervention (PCI) by enabling remote manipulation of guidewires and stent/balloon catheters from a radiation-shielded control station. The platform is built on proprietary bionic technologies including R-Grasp (anthropomorphic joystick control), R-Lock (guidewire locking system), Radio-Stop (total radioprotection for the operator), and an open architecture compatible with all market-leading guidewires, stent/balloon catheters, and cath lab imaging systems. A second-generation robotic platform, designed for complex coronary procedures, completed enrollment in its First-In-Human clinical study in May 2026.

The company operates a hybrid revenue model combining capital equipment sales (R-One+ robotic platforms) with high-margin recurring revenue from single-use consumables and after-sales service/maintenance contracts. Robocath sells primarily through direct enterprise field sales to hospitals with cardiac catheterization laboratories in Europe, while expanding internationally through strategic distribution channels: a 49%-owned CathBot joint venture with MicroPort MedBot for the China and Hong Kong markets (with local assembly and NMPA-approved distribution), and a distribution partnership with Vertice Medtech Group for African markets. The company also pursues a neurovascular expansion strategy via a four-year co-development program with Philips France for stroke interventions. As of April 2026, Stereotaxis announced a definitive agreement to acquire Robocath for up to $45 million, with the transaction expected to close mid-2026. Robocath has raised over €50 million in cumulative funding since inception and employs over 70 people across R&D, production, regulatory affairs, and commercial functions.

Name

Robocath

Legal name

ROBOCATH

Website

https://robocath.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Robocath is a French medical robotics company that designs and commercializes robotic platforms—principally the R-One+ system—for percutaneous coronary intervention, serving interventional cardiology departments in hospitals across Europe, Africa, and China.

Ownership category

akta.pro rank

Product category

Vascular Robotics / Interventional Cardiology Robotics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industry

Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL)

Keywords

• Vascular robotics
• Interventional cardiology
• Robotic coronary intervention
• Endovascular robotics
• Medical robotics systems

Headquarters

HQ city

Rouen

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Robotic System Sales: Sale of R-One and R-One+ robotic platforms to hospitals and medical centers for interventional cardiology procedures
2. Consumables: Single-use instruments and consumables required for each robotic-assisted procedure
3. Service and Maintenance: After-sales services, technical support, and maintenance contracts for installed robotic systems

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Robocath designs, develops, and commercializes robotic platforms for interventional vascular medicine. The flagship product, R-One+, is a CE-marked and NMPA-approved robotic system that assists interventional cardiologists in performing percutaneous coronary intervention (PCI/angioplasty) with precise, remotely controlled manipulation of guidewires and stent/balloon catheters from a radiation-protected workstation. A second-generation robotic platform is currently in First-In-Human clinical trials for complex coronary artery disease, and the company is extending its technology toward neurovascular interventions (stroke and carotid stenting) through partnerships with Philips France and CHU de Rennes.

Product overview

Robocath offers a portfolio of robotic platforms for vascular interventional medicine. The primary commercial product is R-One+, designed for percutaneous coronary intervention (PCI/angioplasty) to treat coronary artery disease. The company is also developing a second-generation robotic platform currently in First-In-Human clinical trials. Through its CathBot joint venture with MicroPort MedBot, the company commercializes its technology in China. R-One+ features open architecture compatible with market-leading guidewires, stent/balloon catheters, and cath lab imaging systems.

Differentiator

Problem solved

Functional benefit

Brands

• R-One+: Enhanced version of Robocath's first robotic platform for percutaneous coronary intervention (PCI). Features R-Grasp, R-Lock, R-Precise technologies, Radio-Stop radioprotection, and open architecture compatible with market-leading devices and cath labs.
• R-One

Products and services

• R-One+ Robotic platform for percutaneous coronary intervention (PCI) assisting interventional cardiologists in stent placement by enabling remote manipulation of guidewires and stent/balloon catheters from a radiation-protected control station. For hospitals and medical centers with cardiac catheterization laboratories (cath labs).
• Second-generation robotic system Next-generation vascular interventional robot with capabilities designed for complex coronary procedures, currently undergoing First-In-Human clinical study at Centre Cardiologique du Nord in Saint-Denis, France.

Quantifiable outcome

• 84.5% average reduction in physician X-ray radiation exposure during coronary angioplasty procedures
• +5 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• StereotaxiscoreStrategic or Co-development Partner · 15 April 2026Definitive agreement signed April 2026 for Stereotaxis to acquire Robocath for up to $45 million ($20M upfront plus up to $25M in contingent payments). Stereotaxis expects approximately $2 million in revenue from Robocath in first year post-acquisition with breakeven by third year. Transaction expected to close mid-2026.
• Philips FrancecoreStrategic or Co-development Partner · 7 July 2021Four-year co-development research program with CHU de Rennes and Philips France for robotic treatment of strokes (AVC). The program aims to improve care for stroke patients using Robocath's R-One robotic platform in neurovascular interventions, with Philips providing imaging technology integration support.
• MicroPort MedBot (Shanghai) Co., Ltd.coreStrategic or Co-development Partner · 2 November 2020Joint venture CathBot created November 2020, owned 51% by MicroPort MedBot and 49% by Robocath, to commercialize R-One in China and develop next-generation vascular robotics. Robocath provides robotic technology while MicroPort provides market access, local manufacturing, and distribution infrastructure. The partnership includes development of 5G-enabled remote vascular interventions and AI integration.
• Vertice Medtech GroupminorChannel Partner/ Reseller/ Distributor · 16 December 2019Distribution partnership for African markets. Vertice Medtech Group distributes R-One platform in South Africa and potentially other African territories, with first installations at Netcare Christiaan Barnard Memorial Hospital in Cape Town.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Philips: Global leader in interventional imaging (Azurion) and active partner of Robocath on the neurovascular/stroke program; broader incumbent that could bundle or compete with vascular robotics offerings.
• Intuitive Surgical: Global leader in surgical robotics (da Vinci) with a much broader portfolio; while not focused on vascular robotics, it represents the dominant robotic-surgery incumbent and could expand into interventional cardiology/neurovascular.
• Medtronic: Global cardiovascular devices leader (stents, catheters, structural heart); sells into the same cath-lab customers as Robocath and has publicly explored robotics for interventional procedures.
• Abbott Vascular: Major cardiovascular device manufacturer with a leading position in coronary stents and cath-lab consumables; overlapping customer base and could integrate robotics into its procedural device portfolio.
• Boston Scientific: Cardiovascular and interventional radiology device company selling stents, balloons, and structural heart products to the same cath-lab customers Robocath targets.
• Siemens Healthineers: Owns Corindus and supplies cath-lab imaging systems (Artis) that integrate with robotic platforms; competes with Robocath on the imaging-integration layer and via its subsidiary.

Direct peers

• Stereotaxis: US-listed robotic systems company developing the Genesis robotic magnetic navigation platform for electrophysiology; pending acquisition of Robocath announced April 2026 makes it both a direct peer in endovascular/interventional robotics and the parent entity going forward.
• Corindus (Siemens Healthineers): Develops the CorPath GRX robotic platform for percutaneous coronary and peripheral vascular interventions — the most direct global competitor to Robocath's R-One+ in vascular robotics, with broader incumbent distribution via Siemens.
• MicroPort MedBot: Robotic surgery subsidiary of MicroPort Scientific and 51% owner of the CathBot JV; develops competing vascular and orthopedic robotic systems in China and is both Robocath's strategic partner and a regional direct competitor.

Emerging players

• Penumbra: Specialist in neurovascular thrombectomy and stroke intervention; Robocath's neurovascular expansion (Sensome partnership, CHU de Rennes carotid program) directly intersects with Penumbra's core franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/robocath

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Robocath